QUANTIFYING PREFERENCES FOR TYPE 2 DIABETES TREATMENTS AMONGST INDIVIDUALS IN ITALY: A DISCRETE CHOICE EXPERIMENT
Author(s)
Helen Kendal, MSc1, Isabella Avantifiori, MSc2, Anya E. Bonam, MSc1, Lucia Sara D'Angiolella, PhD3, Elisabeth de Laguiche, MSc4, Giorgia Guareschi, MSc3, James Turvill, MBiolSci5, Rachel Hiley, MBiol5, Maria Teresa Petrangolini, MSc6.
1Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom, 2FAND Italy – Associazione Italiana Diabetici, Roma, Italy, 3Novo Nordisk Spa, Rome, Italy, 4Novo Nordisk A/S, Søborg, Denmark, 5Adelphi Research, Bollington, United Kingdom, 6ALTEMS – Università Cattolica del Sacro Cuore, Roma, Italy.
1Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom, 2FAND Italy – Associazione Italiana Diabetici, Roma, Italy, 3Novo Nordisk Spa, Rome, Italy, 4Novo Nordisk A/S, Søborg, Denmark, 5Adelphi Research, Bollington, United Kingdom, 6ALTEMS – Università Cattolica del Sacro Cuore, Roma, Italy.
OBJECTIVES: This study evaluated treatment preferences of individuals living with type 2 diabetes (T2D) in Italy, to assess whether a once-weekly (OW) combination therapy of basal insulin and a glucagon-like peptide-1 analogue better aligns to individual preferences than other T2D treatments.
METHODS: An attributes and levels grid was developed following a targeted literature review and interviews with 10 individuals living with T2D in Italy. Attributes and levels were implemented into an online survey and discrete choice experiment (DCE), completed by adults living with T2D from Italy and China between November 2025 and March 2026. Six attributes described administration and benefit-risk outcomes: dose preparation, administration frequency, weight change, cardiovascular (CV) risk factors, HbA1c control and risk of a severe hypoglycaemic (SH) event. Hierarchical Bayesian modelling estimated part-worth utilities (PWUs) for each attribute. Relative importance (RI) of each treatment attribute is reported for the Italy sample.
RESULTS: In total, 225 participants with T2D in Italy completed the survey (mean age 62.1 years; 52% male; mean time since diagnosis 10.1 years; mean BMI 27.4 kg/m2). Administration frequency was the most important attribute relative to other attributes (RI 26%). PWUs indicated a stronger preference for OW versus once-daily administration, while >1 daily administration was least preferred. Weight change emerged as the second most important consideration (RI: 24%), with PWUs showing a stronger preference for weight gain avoidance than achieving weight loss, followed by risk of an SH event (RI: 22%). Remaining attributes had lower importance (HbA1c control [RI: 11%]; CV risk factors [RI: 10%]; dose preparation [RI: 8%]).
CONCLUSIONS: Among Italian participants with T2D, administration frequency was the primary driver of treatment preference, followed closely by weight change (particularly avoidance of weight gain) and risk of an SH event. Findings highlight the potential for OW insulin combination therapies to better align with individual priorities by reducing treatment burden.
METHODS: An attributes and levels grid was developed following a targeted literature review and interviews with 10 individuals living with T2D in Italy. Attributes and levels were implemented into an online survey and discrete choice experiment (DCE), completed by adults living with T2D from Italy and China between November 2025 and March 2026. Six attributes described administration and benefit-risk outcomes: dose preparation, administration frequency, weight change, cardiovascular (CV) risk factors, HbA1c control and risk of a severe hypoglycaemic (SH) event. Hierarchical Bayesian modelling estimated part-worth utilities (PWUs) for each attribute. Relative importance (RI) of each treatment attribute is reported for the Italy sample.
RESULTS: In total, 225 participants with T2D in Italy completed the survey (mean age 62.1 years; 52% male; mean time since diagnosis 10.1 years; mean BMI 27.4 kg/m2). Administration frequency was the most important attribute relative to other attributes (RI 26%). PWUs indicated a stronger preference for OW versus once-daily administration, while >1 daily administration was least preferred. Weight change emerged as the second most important consideration (RI: 24%), with PWUs showing a stronger preference for weight gain avoidance than achieving weight loss, followed by risk of an SH event (RI: 22%). Remaining attributes had lower importance (HbA1c control [RI: 11%]; CV risk factors [RI: 10%]; dose preparation [RI: 8%]).
CONCLUSIONS: Among Italian participants with T2D, administration frequency was the primary driver of treatment preference, followed closely by weight change (particularly avoidance of weight gain) and risk of an SH event. Findings highlight the potential for OW insulin combination therapies to better align with individual priorities by reducing treatment burden.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR56
Topic
Patient-Centered Research
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)